Z160
Z160 is an investigational drug that was developed as a potential treatment for chronic pain. It is a novel, oral, state-dependent, selective N-type calcium channel blocker. Z160 was designed to modulate the activity of N-type calcium channels, which are known to play a critical role in the transmission of pain signals in the nervous system.
Mechanism of Action[edit | edit source]
Z160 works by selectively blocking N-type calcium channels, which are located on the presynaptic terminals of neurons. These channels are involved in the release of neurotransmitters that propagate pain signals. By inhibiting these channels, Z160 reduces the release of neurotransmitters, thereby diminishing the transmission of pain signals to the brain.
Clinical Development[edit | edit source]
Z160 was developed by Zalicus Inc., a biopharmaceutical company focused on the development of treatments for pain and inflammation. The drug underwent several clinical trials to evaluate its efficacy and safety in treating chronic pain conditions such as neuropathic pain and fibromyalgia.
Phase I Trials[edit | edit source]
In Phase I clinical trials, Z160 was tested for safety, tolerability, and pharmacokinetics in healthy volunteers. The results indicated that Z160 was well-tolerated with a favorable safety profile.
Phase II Trials[edit | edit source]
Phase II trials were conducted to assess the efficacy of Z160 in patients with chronic pain conditions. However, the results of these trials were mixed, with some studies failing to demonstrate significant pain relief compared to placebo.
Challenges and Future Directions[edit | edit source]
Despite the initial promise of Z160, the challenges in demonstrating consistent efficacy in clinical trials have highlighted the complexity of targeting N-type calcium channels for pain management. Further research is needed to better understand the pharmacodynamics and potential therapeutic applications of Z160.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
